FIGURE 1 | Shape change of neutrophils, the most elegant response to chemo-attractants, observed within seconds of challenge, and characterized by the protrusion and retraction of ectoplasmic extensions, due to polymerization and breakdown of actin. The protrusions appear to function like a swimmer's arms and legs. Turbidity recordings suggest that the changes are synchronized, possibly to facilitate migration (11) . Scanning electron micrograph by Matthias Wyman, a former Ph.D. student at TKI, now professor at the University of Basel.
Ivan Lindley, Heinz Aschauer, and other colleagues at the Sandoz Research Institute in Vienna, who had sequenced our purified protein, went a few steps further. They synthesized a gene coding for the 72-residue NAF, which they cloned and expressed. The recombinant protein was analyzed at the TKI, and found to be identical in activity and potency to purified, natural NAF (6).
The first chemokine had been thoroughly characterized, but still did not have a name. None of the acronyms used in the papers reporting isolation, sequencing, cloning, and expression (MDNCF, NAF, MONAP, LYNAP, etc.) being suitable, the new protein ended up with a fancy but misleading name: "interleukin 8. " It was the first and the last chemokine to be taken for an interleukin.
Four papers putting forward the same message indicated that the chemokine area was important and competitive. I went to Frederick to see Ed Leonard, Jo Oppenheim, and colleagues and discuss possible collaborations. For me, that visit was also a chance to meet Teizo Yoshimura and Kouji Matsushima. We decided to continue our friendly relations without a formal collaboration, which was reasonable since there was no way of knowing how things would develop in the field and how research in our laboratories would evolve. In line with TKI traditions, we characterized NAF/IL8 using biochemical and biophysical methods, as shown in the comparison of neutrophil responses to NAF/IL8 and fMet-Leu-Phe by Thelen et al. (7) . Real-time recordings of changes in cell shape, cytosolic free calcium levels, superoxide formation, and granule enzyme release showed that the responses to both chemo-attractants followed similar kinetics. In addition, the effects of both agonists were inhibited to a similar extent by pretreating the neutrophils with B. pertussis toxin and other inhibitors of signal transduction. Despite the similarities in response quality, we observed a clear difference between the two agonists in terms of potency, with NAF/IL8 being 10-30 times more effective than fMet-Leu-Phe.
I emphasized that NAF/IL8 is highly selective for neutrophils, but I cannot end this brief account without pointing out that the first chemokine had, in fact, additional attractant properties, with unique scientific implications: for one thing, it attracted two brilliant scientists from Vancouver to Bern, Bernhard Moser and Ian Clark-Lewis. They were both primarily interested in NAF/IL8 and wanted to identify its receptor. They also expected to find new chemokines and new receptors, and eventually to study the structural determinants for receptor recognition and activation. Bernhard Moser went to school in Bern, studied at ETH Zurich, and obtained a PhD degree at the University of British Columbia before returning to Bern to clone and characterize chemokine receptors, and to study white cell traffic in immune defense. Ian Clark-Lewis was introduced to immunology at the famous Walter and Eliza Hall Institute of Medical Research in Melbourne and specialized in chemical protein synthesis in the US and in Canada. At the Biomedical Research Centre of the University of British Columbia, he established an impressive facility for solid-phase protein synthesis. Chemokines impressed him as a promising area for studying structure-activity relations and for the design of chemically-modified analogs including receptor antagonists.
From among the thirty and more publications witnessing the productive collaboration between Ian, Bernhard and other scientists at the TKI for more than a decade, I shall quote three highlights relating to NAF/IL8. Early structure-activity relation studies identified the short amino-terminal sequence preceding the first cysteine as the site for receptor binding and triggering (8), a principle that turned out to be valid for the whole chemokine family, underscoring the prototypical value of NAF/IL8. A very extensive study using a large sample of synthetic analogs with single amino-acid exchanges revealed that except for the cysteines and the ELR motif no other residue appeared to be required for NAF/IL8 receptor binding and activity (9) . The same study showed, in addition, that IP10 (a CXC chemokine that does not activate neutrophils) can be modified to a potent attractant of neutrophils by insertion of discrete sequence domains taken from the NAF/IL8 amino-terminal loop (9) . Ian also answered a fundamental question that was raised after observing that NAF/IL8 forms dimers in solution: do chemokines act as monomers or dimers? By replacing Leu in position 25 with N-methyl-Leu in the NAF/IL8 sequence, he created a derivative that could not dimerize but nevertheless retained full activity (10), indicating that NAF/IL8 binds to its receptors and trigger responses as a monomer. For Bernhard Moser the work on IL8 and receptors was a sort of high-level warming up. Bernhard's major achievements came a few years later, with Marcel Loetscher and Pius Loetscher as associates, and several Ph.D. students, after moving on to arenas, which were increasingly populated by lymphocytes.
Ian Clark-Lewis died prematurely in 2002. He is much missed by those who worked with him, and saw him as a distinguished TKI-member from the West coast. He did not mind long-distance travel, and visited us regularly. He frequently took time to discuss scientific issues on the phone, in long, remarkable conversations. From Vancouver, he had set up a productive network of contacts and friendly relations with many of us.
